Biogen Inc. stock gains after new EMPAVELI kidney data publication

Published on 09/18/2026 at 23:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Biogen Inc. stock closed at USD 219.05 on Nasdaq on September 17, 2026 after the company published Phase 3 adolescent EMPAVELI data in kidney disease. The shares are up more than 20 percent year to date, with investors watching trial results and guidance for further catalysts.

Fotorealistisches Biotech-Labor in Cambridge MA mit Forscherin am Mikroskop und Blick auf den Charles River — Biogen Inc. Neurowissenschaftslabor in Cambridge MA zeigt Forscherin bei Gehirngewebeanalyse unter Mikroskop ISIN US09062X1037, Illustration mit AI erstellt.

Biogen Inc. stock (ISIN US09062X1037) closed at USD 219.05 on the Nasdaq on September 17, 2026, up 1.41 percent from the prior close, with after-hours trading later showing USD 217.01 as investors digested new data for its kidney disease therapy EMPAVELI. According to RTTNews on September 18, 2026, the stock reaction followed the publication of Phase 3 adolescent data showing reduced proteinuria in chronic kidney conditions.

EMPAVELI kidney data underpins Biogen Inc. stock

Biogen Inc., the US biotechnology group best known for its neurology portfolio, highlighted fresh results from a prespecified adolescent subgroup of the Phase 3 VALIANT study evaluating EMPAVELI (pegcetacoplan) in complement-mediated kidney diseases. As GlobeNewswire via Ritzau reported on September 17, 2026, Biogen announced results from an adolescent subgroup analysis in the Phase 3 VALIANT study, showing EMPAVELI reduced proteinuria in patients with C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

The company emphasized that reduced proteinuria is clinically meaningful because sustained high levels are associated with faster kidney function decline. According to GlobeNewswire via Ritzau, EMPAVELI is being evaluated as a potential first disease-modifying therapy in these rare complement-driven conditions, extending Biogen's footprint beyond neurology into nephrology. For investors, the new data add to the company’s pipeline narrative and may help support valuation ahead of the next set of financial results.

Stock performance, valuation and recent fundamental picture

Biogen Inc. shares have performed strongly over the past year. A recent analysis noted that the stock moved from USD 143.81 on September 18, 2025 to USD 218.32 on September 18, 2026, corresponding to a gain of 51.81 percent over 12 months. According to an investor article summarizing the move, Biogen also set a 52-week high of USD 224.51 on September 3, 2026, placing the latest closing price less than 3 percent below that peak and underlining the constructive trend for the stock.

The same analysis put Biogen’s market capitalization at USD 32.26 billion as of September 18, 2026 and cited a trailing price-earnings ratio of 38.8, while noting that on the company’s 2026 earnings forecast of USD 12.00 to 13.00 per share the forward multiple would drop to roughly 17 times. These figures, based on recent company guidance for fiscal year 2026 and aggregated by investor commentary, show that Biogen Inc. stock has rerated significantly compared with a year earlier but is valued more moderately on expected earnings, which may appeal to investors looking for exposure to specialty biotech with late-stage assets.

Year to date, Biogen Inc. stock has also advanced clearly. Per MarketBeat data updated around September 18, 2026, Biogen shares started the year at USD 175.99 and were recently trading at USD 219.05, an increase of 24.5 percent year to date. That performance outpaces many large-cap biopharma peers and suggests investors have rewarded Biogen for progress with its Alzheimer’s collaboration and its broader pipeline, including the EMPAVELI kidney program.

Analyst attention and upcoming catalysts

The latest EMPAVELI publication has also appeared in market notes, signaling that the story is on the radar of institutional desks. For example, a morning note from CAPIS on September 18, 2026 highlighted Biogen’s publication of Phase 3 adolescent EMPAVELI data in C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis, underscoring that the trial remains a key driver for sentiment in the name. According to CAPIS, the publication contributed to Biogen being mentioned among notable corporate developments as indexes recovered for the week.

While specific new analyst rating changes or price-target revisions for Biogen within the past few days are not singled out in the available sources, the combination of a more than 50 percent share price gain over 12 months and forward earnings guidance in the USD 12.00 to 13.00 range for 2026 sets a framework for analyst models. Many investors will now watch how EMPAVELI’s kidney data translate into regulatory discussions and eventual commercial potential, alongside Biogen’s established neurology portfolio. The key risk is execution across multiple therapeutic areas and potential competition in complement-mediated disease, but the latest data help demonstrate clinical activity in a difficult-to-treat population.

Biogen Inc. stock near its yearly high

As of the close on September 17, 2026, Biogen Inc. stock traded at USD 219.05 on the Nasdaq, with after-hours levels around USD 217.01 indicating only a modest pullback from that close and leaving the shares within a few dollars of the recent 52-week high of USD 224.51. The move from USD 143.81 a year earlier to more than USD 218 represents a gain of 51.81 percent over 12 months, while the year-to-date performance of 24.5 percent reflects investors’ confidence in Biogen’s earnings guidance of USD 12.00 to 13.00 per share for 2026 and in the incremental pipeline news such as the EMPAVELI kidney data.